Low dose colestipol in adolescents with familial hypercholesterolaemia
- PMID: 8660081
- PMCID: PMC1511517
- DOI: 10.1136/adc.74.2.157
Low dose colestipol in adolescents with familial hypercholesterolaemia
Abstract
The effects of orange flavoured colestipol granules, 10 g/day, in 37 boys and 29 girls aged 10-16 years with familial hypercholesterolaemia were examined first in an eight week double blind, placebo controlled protocol, then in open treatment for 44-52 weeks. All patients were on a low fat diet. Low density lipoprotein cholesterol levels were reduced by 19.5% by colestipol v 1.0% by placebo. Levels of serum folate, vitamin E, and carotenoids were reduced in the colestipol group, but not the vitamin E/cholesterol and carotenoid/cholesterol ratios or serum concentrations of vitamins A and D. After one year of colestipol, two thirds of the participants remained in the study, of whom half took > or = 80% of the prescribed dose. Those who took > or = 80% of the dose had a greater decrease in serum 25-hydroxyvitamin D levels than those who took < 80%. No adverse effects on weight gain or linear growth velocity were observed. Although low dose colestipol effectively reduces low density lipoprotein cholesterol levels, only a minority of adolescents adhered to the new formulation for one year. Folate and possibly vitamin D supplementation is recommended.
Similar articles
-
Colestipol tablets in adolescents with familial hypercholesterolaemia.Acta Paediatr. 1996 Sep;85(9):1080-2. doi: 10.1111/j.1651-2227.1996.tb14221.x. Acta Paediatr. 1996. PMID: 8888922 Clinical Trial.
-
Fenofibrate and colestipol: effects on serum and lipoprotein lipids and apolipoproteins in familial hypercholesterolaemia.Eur J Clin Pharmacol. 1986;30(2):191-4. doi: 10.1007/BF00614301. Eur J Clin Pharmacol. 1986. PMID: 3709644
-
"Low dose" colestipol in children, adolescents and young adults with familial hypercholesterolemia.Atherosclerosis. 1982 Jan;41(1):133-8. doi: 10.1016/0021-9150(82)90077-6. Atherosclerosis. 1982. PMID: 7073790 Clinical Trial.
-
Colestipol: a review of its pharmacological properties and therapeutic efficacy in patients with hypercholesterolaemia.Drugs. 1980 Mar;19(3):161-80. doi: 10.2165/00003495-198019030-00001. Drugs. 1980. PMID: 6988203 Review.
-
Colestipol.2022 Sep 19. Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. 2022 Sep 19. Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. PMID: 30000452 Free Books & Documents. Review.
Cited by
-
The Role of Non-statin Lipid-Lowering Medications in Youth with Hypercholesterolemia.Curr Atheroscler Rep. 2022 May;24(5):379-389. doi: 10.1007/s11883-022-01013-x. Epub 2022 Mar 28. Curr Atheroscler Rep. 2022. PMID: 35344138 Review.
-
A rational approach to treating hypercholesterolaemia in children. Weighing the risks and benefits.Drug Saf. 1997 May;16(5):330-41. doi: 10.2165/00002018-199716050-00004. Drug Saf. 1997. PMID: 9187532 Review.
-
Dyslipidemia and cardiovascular health in childhood nephrotic syndrome.Pediatr Nephrol. 2020 Sep;35(9):1601-1619. doi: 10.1007/s00467-019-04301-y. Epub 2019 Jul 13. Pediatr Nephrol. 2020. PMID: 31302760 Review.
-
The genetics of familial hypercholesterolemia and emerging therapies.Appl Clin Genet. 2015 Jan 28;8:27-36. doi: 10.2147/TACG.S44315. eCollection 2015. Appl Clin Genet. 2015. PMID: 25670911 Free PMC article. Review.
-
Role of lipid-lowering pharmacotherapy in children.Paediatr Drugs. 2000 Jan-Feb;2(1):11-22. doi: 10.2165/00148581-200002010-00002. Paediatr Drugs. 2000. PMID: 10937455 Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical